Cancer Epidemiology is the study of the distribution, frequency, determinants, causes and outcomes of cancer in populations. It asks questions such as how often particular cancers occur, how incidence varies by age, sex, geography or socioeconomic circumstances, which exposures are associated with disease, how survival changes over time, and how prevention or screening programmes influence population outcomes. Epidemiology differs from the study of an individual patient because its principal unit of analysis is a population or defined group. It provides the quantitative evidence needed to understand cancer burden, identify risk factors, evaluate interventions and allocate health resources.
Key epidemiological measures include incidence, prevalence, mortality, survival and case-fatality. Incidence measures newly diagnosed cases during a specified period in a defined population, whereas prevalence measures people living with the disease at a particular time or over a period. Mortality measures deaths attributable to cancer, and survival describes the proportion of patients remaining alive after a specified interval from diagnosis. Age-standardised rates are particularly important when comparing populations with different age structures. Without appropriate denominators, time periods and population definitions, apparently large differences in cancer burden can be misleading.
Cancer Epidemiology investigates causal and non-causal associations using observational and experimental methods. Cohort studies can follow exposed and unexposed groups over time, while case-control studies compare previous exposures among people with and without a particular cancer. Cross-sectional studies provide information at a defined point in time, and randomised trials can provide strong evidence about interventions. Epidemiologists account for confounding, selection bias, information bias and chance when interpreting associations. Relative risk, odds ratios, hazard ratios, absolute risks and population-attributable measures answer different questions and should not be treated as interchangeable.
The field has established strong relationships between numerous exposures and specific cancers. Tobacco use is a major preventable cause of cancer and is particularly important for lung cancer, while occupational exposures, radiation, infectious agents, alcohol, obesity, diet, physical inactivity and environmental pollution contribute to cancer risk in varying ways. WHO estimates that cancer caused nearly 10 million deaths globally in 2024 and identifies lung, breast, colorectal and prostate cancers among the most common cancers. Such figures describe population burden rather than an individual's personal probability of developing cancer.
Cancer Epidemiology also examines disparities in incidence, mortality and survival. Differences can arise from variations in exposure, socioeconomic circumstances, occupational conditions, environmental hazards, health behaviours, screening access, diagnostic delays, treatment availability, health-system capacity and competing causes of death. Breast cancer illustrates the complexity of these patterns: WHO reports substantial differences in breast cancer incidence and mortality across countries according to levels of human development, demonstrating that disease burden is influenced not only by biological risk but also by the capacity to detect and treat disease.
Screening is an important epidemiological application because screening programmes can alter the stage distribution at diagnosis and potentially reduce mortality when they detect clinically important disease early and are accompanied by effective treatment. Epidemiologists distinguish mortality reduction from changes in incidence, detection rates and survival. Earlier diagnosis can increase measured survival time without necessarily reducing the number of deaths in certain circumstances, a phenomenon related to lead-time bias. Overdiagnosis can also identify cancers that would never have caused symptoms or death, potentially increasing apparent incidence and survival while exposing individuals to unnecessary treatment. These methodological issues are essential when evaluating screening programmes.
Cancer registries are central to Cancer Epidemiology because they systematically collect information about cancer diagnoses, tumour characteristics and outcomes. Population-based registries can support monitoring of incidence, survival, geographic variation and temporal trends, while specialised datasets can support research into treatment and prognosis. International organisations such as the International Agency for Research on Cancer compile global cancer estimates that enable comparisons across countries and periods. Current international data show lung cancer as the leading cancer by incidence and mortality globally, with IARC estimating almost 2.65 million lung cancer diagnoses and more than 1.8 million deaths in 2024.
Cancer Epidemiology directly informs prevention policy, screening recommendations, clinical-service planning and research priorities. Its conclusions must nevertheless be interpreted in relation to the population studied, measurement methods, exposure definitions and time period. A population-level association does not necessarily establish that every individual exposed to a factor will develop cancer, and correlations can arise through confounding or other biases. Epidemiological reasoning therefore combines statistical analysis with biological plausibility, study design, consistency of evidence and careful assessment of alternative explanations. Its broader significance is that it converts patterns of cancer occurrence into evidence that can guide population-level prevention and control while distinguishing measurable risk from deterministic claims.
